TOT BIOPHARM International Company Limited reported unaudited consolidated earnings results for the six months ended 30 June 2021. For the six months, the company reported revenue of RMB 23,132,000 compared to RMB 13,030,000 a year ago. Operating loss was RMB 115,445,000 compared to RMB 128,363,000 a year ago. Loss for the period and attributable to the equity holders of the company was RMB 115,005,000 or RMB 0.20 per basic share compared to RMB 129,183,000 or RMB 0.23 per basic share a year ago.